title: Everolimus Boosts Endocrine Therapy for Breast Cancer.
abstract: In a phase II trial, the mTOR inhibitor everolimus, combined with the endocrine therapy fulvestrant, improved progression-free survival in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer who had become resistant to aromatase inhibitors.
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D004357:Drug Synergism; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068338:Everolimus / Q000627:therapeutic use*; D005260:Female; D000077267:Fulvestrant; D006801:Humans; D017698:Postmenopause; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000077267:Fulvestrant; D004958:Estradiol; D000068338:Everolimus